ADC	Antibody–drug conjugate
Ala	Alanine
BV	Brentuximab vedotin
Cit	Citrulline
Cys	Cysteine
DAR	Drug–Antibody Ratio
Dato-DXd	Datopotamab deruxtecan
DM1	Mertansine/emtansine (maytansinoid)
DM4	Soravtansine/ravtansine (maytansinoid)
DOX	Doxorubicin
DS-8201a	Trastuzumab deruxtecan
DXd	Exatecan derivative
EMA	European Medicines Agency
Fabs	Antigen-binding fragments
Fc	Fragment crystallizable region
FDA	Food and Drug Administration
G2	Second growth phase
GO	Gemtuzumab ozogamicin
HER2	Human epidermal growth factor receptor 2
huC242-SPDB-DM4	Cantuzumab ravtansine
Le(Y)	Anti-Lewis Y
Lys	Lysine
M	Mitosis
mAb	Monoclonal antibody
MC	Maleimidocaproyl
MK-2870	Sacituzumab tirumotecan
MMAE	Monomethyl auristatin E
MRG002	Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
MRG003	Anti-Epidermal Growth Factor Receptor Antibody Drug Conjugate
NSCLC	Non-small cell lung cancer
PABC	P-aminobenzyloxycarbonyl
PBD	Pyrrolobenzodiazepine dimer
PEG	Polyethylene glycol
Phe	Phenylalanine
PK	Pharmacokinetics
RC48	Disitamab vedotin
R-DXd	Raludotatug deruxtecan
SG	Sacituzumab govitecan
SN-38	Active metabolite of iridotecan
SSC	Site-specific conjugation
T-DM1	Trastuzumab emtansine conjugate DM1
TNBC	Triple-negative breast cancer
Val	Valine